$4.31+0.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Company outlook: revenue of $100.5M to $111M for Fiscal year 2026 — down 9.3% on a year earlier ($116.6M)
Just reported
From Gyre Therapeutics, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$32.9M
+0.7% y/y
+13% q/q
Guided
—
No guide given
Actual
-$0.04
Guided
—
No guide given
Actual
-$1.5M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $32.9M | $32.7M | +0.73% |
| Profit | -$2.5M | $1.9M | -228.59% |
| Profit per share | -$0.04 | $0.01 | -500.00% |
| Free Cash Flow | -$5M | -$3.3M | -49.34% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Gyre Therapeutics, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
F351 is Gyre’s lead development candidate for the treatment of liver fibrosis that is being developed for two different indications. It is a structurally modified derivative of pirfenidone designed to optimize metabolic properties while targeting the TGF-β1 signaling pathway, a key mediator of fibrogenesis. Gyre is developing F351 for two primary indications: CHB-associated liver fibrosis in the PRC and MASH-associated liver fibrosis for global markets. Gyre has completed a Phase 1 U.S. clinical trial in healthy volunteers evaluating F351’s safety, tolerability, and pharmacokinetics (PK). Gyre is further analyzing Phase 3 study results generated in China, together with new pre-clinical results to determine an optimal regulatory path for global Phase 2 studies in MASH fibrosis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Gyre Therapeutics, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.